Participate

CAN-BIND-2 Validation Study

The objective of this study is to integrate detailed clinical, neuroimaging, EEG, and molecular data to predict treatment outcome for patients experiencing a Major Depressive Episode (MDE), and receiving pharmacotherapy reflective of standard practice. Stool samples will also be collected to integrate microbiota measures into data analyses, as well as blood samples for genomic profiling.

The CAN-BIND Validation cohort will consist of participants who are diagnosed with clinical depression, and are currently experiencing a depressive episode. Participation in this study lasts for 16 weeks from the time participants begin taking their medication.

Participants will receive standard, open-label treatment. For the first eight weeks, patients will receive evidence-based, antidepressant treatment with Cipralex® (escitalopram) (10-20mg). After eight weeks, patients who responded to the medication will continue on their effective dose and will be followed for a further 8 weeks. Those who did not respond to treatment will receive open-label, add-on medication with Rexulti® (brexpiprazole) (0.5-2mg). Clinical, neurophysiology, molecular biomarker, and neuroimaging evaluations will be conducted regularly (approximately every 2-4 weeks) for the duration of treatment.

To learn more about CAN-BIND, visit our website.